as 09-01-2025 9:39am EST
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | MOUNTAIN VIEW |
Market Cap: | 44.6M | IPO Year: | 2021 |
Target Price: | $7.50 | AVG Volume (30 days): | 241.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.36 | EPS Growth: | N/A |
52 Week Low/High: | $0.75 - $1.69 | Next Earning Date: | 08-14-2025 |
Revenue: | $662,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | 2988.37% | Revenue Growth (next year): | 300.60% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Bagai Shaun | RNXT | Chief Executive Officer | Aug 25 '25 | Buy | $0.91 | 5,000 | $4,549.00 | 330,040 | |
Bagai Shaun | RNXT | Chief Executive Officer | Aug 22 '25 | Buy | $0.95 | 5,000 | $4,747.50 | 330,040 | |
Agah Ramtin | RNXT | Chief Medical Officer | Jun 5 '25 | Buy | $1.40 | 21,000 | $29,400.00 | 734,460 |
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
Argus Research
2 months ago
Argus Research
2 months ago
Argus Research
2 months ago
Argus Research
2 months ago
Argus Research
2 months ago
Argus Research
2 months ago
Argus Research
2 months ago
Argus Research
3 months ago
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.